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Epidermal growth factor receptor (EGFR) is one of the most appropriate target molecules for cancer therapy because of its relatively
high expression in about one-third of all epithelial cancers in correlation with neoplasmic progression. With respect to EGFR-targeted
therapies, antibodies and tyrosine-kinase inhibitors have been intensively studied, a novel EGFR-tyrosine-kinase inhibitor ZD1839 has
been approved as an anticancer drug, and many other agents are now under clinical trial. In addition, cytotoxic T lymphocyte (CTL)-
directed epitope peptides could be another class of compounds useful in EGFR-targeted therapies. However, there is presently no
information on CTL-directed peptides of EGFR. Therefore, from the viewpoint of development of peptide-based cancer therapy, this
study was intended to determine the EGFR-derived peptides recognised by both cellular and humoral immunities in HLA-A2
þ
epithelial cancer patients. We herein report finding of two such types of EGFR-derived peptides at position 479–488 and 1138–
1147, both of which were recognised by the majority of patients’ sera (IgG), and also possessed the ability to induce HLA-A2-
restricted peptide-specific CTLs against EGFR-positive tumour cells in peripheral blood mononuclear cells (PBMCs) of epithelial
cancer patients. These results may provide a scientific basis for the development of EGFR-based immunotherapy for HLA-A2
þ
cancer patients.
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Epithelial growth factor receptor (EGFR) plays an important role
in epithelial biology and in many human malignancies (Coussens
et al, 1985; Yamamoto et al, 1986; Salomon et al, 1995). A line of
evidence that the EGFR plays a role in the pathogenesis of various
cancers has led to the rational design and development of agents
that selectively inhibit this receptor. Classes of compounds used in
these EGFR-targeted therapies are mainly antibodies (Abs) and
tyrosine-kinase inhibitors. Among them, ZD1839 (Iressa) is
therapeutically effective for patients with advanced non-small-cell
lung cancer (NSCLC) (Fukuoka et al, 2003; Miller et al, 2003). In
addition, cytotoxic T lymphocyte (CTL)-directed epitopes could be
another class of compound useful in EGFR-targeted therapies as
peptide vaccines for cancer patients whose tumours overexpress
EGFR. However, there is little information on CTL-directed
epitopes of EGFR, although such CTL-directed peptides of
HER2/neu, a family of EGFR, have been reported over the past
decade (Fisk et al, 1995; Peoples et al, 1995; Kawashima et al, 1999;
Okugawa et al, 2000). In previous clinical studies, we reported that
some CTL-directed peptides from nonmutated proliferation-
related proteins had the ability to elicit both cellular and humoral
immune responses in vivo (Mine et al, 2003; Noguchi et al, 2003;
Sato et al, 2003). Further, the levels of antipeptide Abs in
postvaccination sera were well correlated with the overall survival
of advanced lung cancer patients who received peptide vaccination
(Mine et al, 2003). In addition, there is a line of evidence
suggesting the existence of more highly immunogenic peptides
that are capable of inducing both cellular and humoral immune
responses (Disis et al, 1997). Therefore, to assist in the
development of peptide-based cancer therapy, we here attempted
to identify such peptides, and report the discovery of two peptides
that can be considered as vaccine candidates for HLA-A2
þ cancer
patients.
MATERIALS AND METHODS
Samples and cell lines
After written informed consent was obtained, sera and peripheral
blood mononuclear cells (PBMCs) were collected from NSCLC
patients at Kurume University Hospital. Peripheral blood mono-
nuclear cells and sera were also obtained from healthy donors
(HDs). All subjects were free from human immunodeficiency virus
(HIV) infection. All sera and PBMCs were cryopreserved at  80
and  1961C until use, respectively. The expression of HLA-class I
antigens on these PBMCs was serologically defined by the
conventional methods as reported previously (Noguchi et al,
2003), and HLA-A2 subtypes were determined by the sequence-
specific oligonucleotide probe method as reported previously (Ito
et al, 2001). The following tumour cell lines were used as target
cells in a 6-h
51Cr-release assay in this study: 11–18 (HLA-A2/24,
human lung adenocarcinoma, EGFR
þ), QG56 (HLA-A26, human
lung squamous cell carcinoma, EGFR
þ), SKOV3 (HLA-A3/28,
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þ) and SKOV3-A2 (HLA-A2-
transfected SKOV3). The expression of EGFR in these cell lines
except 11-18 was already reported (Xu et al, 1999; Hasmann et al,
2003). The expression of EGFR in 11-18 tumour cells was checked
by flow cytometric assay with an immunofluorescence-labelled
anti-EGFR monoclonal antibody (mAb) (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, USA) (Parkar et al, 2001), and it was also
expressed in 11–18 tumour cells (data not shown). Phytohaemag-
glutinin (PHA)-blastoid T cells from PBMCs were also used as a
negative control of target cells for a 6-h
51Cr-release assay. For
peptide loading, T2 (HLA-A2, T-B hybridoma) cells were also used
in this study.
Peptides and quantification of antipeptide-specific IgG
The following peptides were purchased from BioSynthesis (Lewis-
ville, TX, USA): 29 kinds of EGFR-derived peptides with HLA-
A0201 and A0205 binding motifs at positions 10–18, 40–49, 61–
70, 88–96, 110–118, 431–440, 479–488, 599–607, 653–662, 654–
662, 656–664, 665–674, 681–689, 702–800, 717–725, 729–738,
765–776, 777–786, 791–799, 811–819, 813–822, 813–821, 843–
851, 852–861, 944–952, 944–953, 945–953, 1001–1010, and
1138–1147, respectively. An HIV peptide with an HLA-A0201
binding motif (SLYNTVATL) was also provided as a negative
control. Antipeptide-specific IgG levels in sera were measured by
an enzyme-linked immunosorbent assay (ELISA) as reported
previously (Sato et al, 2003). In brief, serum samples were serially
diluted with 0.05% Tween 20-Block Ace (Yukijirushi Nyugyo,
Tokyo, Japan), and 100mlwell
 1 of diluted serum was added to the
peptide (20mgwell
 1)-immobilized Nunc Covalink plates (Ros-
kilde, Denmark). Antipeptide Abs were detected with a rabbit anti-
human IgG (g-chain-specific) (DAKO, Glostrup, Denmark). For
determining the limit of sensitivity of ELISA, sera from 11 HDs
(HIV-negative) were measured for their reactivity to an HIV
peptide by the assays, and the mean72 standard deviations (s.d.)
of optimal density (OD) at a serum dilution of 1:100 was
0.0270.04. The meanþ2 s.d. value (0.06) was then determined as
the cutoff value. To test the specificity of antipeptide IgG in serum
samples, 100mlwell
 1 of serum samples (100 times dilution with
0.05% Tween 20-Block Ace) was absorbed with immobilised
peptides (20mgwell
 1) in wells of the plate for 2h at 371C. The
absorption, followed by testing of the antipeptide IgG with ELISA,
was repeated three times. To test the antipeptide IgG response to a
whole molecule of EGFR, patients’ sera possessing antipeptide
activity were also absorbed with either immobilised human EGFR
isolated from A431 cells with a purity of 85% (UPSTATE,
Charlottesville, VA, USA) or immobilised human albumin as a
negative control, followed by measurement of anti-peptide activity
by ELISA.
To test the direct growth inhibition activity of antipeptide IgG,
11–18 tumour cells were cultured in the presence of three different
concentrations of sera that had detectable levels of antipeptide
activity. Namely, 11–18 cells at 1 10
3 cellswell
 1 in a 96-well
microculture plate (IWAKI, Chiba, Japan) were cultured for 12h in
the medium with 10% FCS followed by replacement of the culture
medium to serum-free RPMI1640 with 1, 2, or 5% of serum
possessing antipeptide activity. As controls, these sera absorbed
with a corresponding peptide, sera without antipeptide activity
from the two patients and two HDs were used. A total of 11–18
cells were also cultured in the RPMI1640 with 1, 2 and 5% FCS,
respectively. After 24, 48 and 72h incubation, the number of viable
cells was determined by Cell Counting Kit-8 (Dojindo, Kumamoto,
Japan). We also tested the antibody-dependent cell-mediated
cytotoxicity of antipeptide IgG. Namely, the cytotoxicity of freshly-
isolated PBMCs from HLA-A2
þ HDs against T2 cell pulsed with an
EGFR-derived peptide or an HIV peptide as a negative control was
measured in the presence of heat-inactivated serum possessing
antipeptide activity by a standard 6-h
51Cr-release assay. As
controls, these sera absorbed with a corresponding peptide, sera
possessing nonpeptide activity, and serum-free RPMI1640 medium
were used. All sera used in the cytotoxicity assay were heat-
inactivated at 561C for 30min.
CTL induction
Peripheral blood mononuclear cells from HLA-A2
þ epithelial
cancer patients and HDs served as samples for the CTL induction
assay. For induction of peptide-specific CTLs, PBMCs (15 10
4
cellswell
 1) were incubated with 10mM of each peptide in four
different wells of a 96-well microculture plate (Nunc) in 200ml
culture medium containing interleukin-2 (IL-2), as reported
previously (Mine et al, 2003). On the 14th day, the cells from
each well were independently harvested, washed, and tested for
their ability to produce interferon-g (IFN-g) in response to T2 cells
pulsed with a corresponding peptide or a negative control peptide
(HIV) in the duplicate assays. After an 18-h incubation, the
supernatant was collected and measured for IFN-g production by
ELISA. Then the cells in the wells producing IFN-g in response to a
corresponding peptide were collected and further cultured with IL-
2 alone for 10–14 days to obtain a large number of cells for a
standard 6-h
51Cr-release assay against the various tumour cells
described above. The method used for the
51Cr-release assay has
been reported elsewhere (Mine et al, 2003). For an inhibition test,
we used 20mg/ml of anti-HLA-class I (W6/32, IgG2a), anti-HLA-
class II (H-DR-1, IgG2a), anti-CD4 (Nu-Th/i, IgG1), and anti-CD8
(Nu-Ts/c, IgG2a) mAbs. We also used an anti-CD14 (JML-H14,
IgG2a) mAb as a negative control. For a competition assay to study
the peptide specificity of the cytotoxicity, unlabelled T2 cells
pulsed with the corresponding peptide or an HIV peptide as a
negative control were added to the
51Cr-release assay at a cold-to-
hot target cell ratio of 10:1. A two-tailed Student’s t-test was
employed for the statistical analysis in this study.
RESULTS
We first investigated whether IgG reactive to each of the 29
different EGFR-derived peptides could be detected in the sera of 20
cancer patients and 11 HDs. Representative results are shown in
Figure 1 and a summary of the results on 11 different peptides to
which at least two of the sera showed a positive response is given
in Table 1. Significant levels of IgG (40.06 OD values at a serum
dilution of 1:100) reactive to the EGFR479-488, EGFR729-738, and
EGFR1138-1147 peptides were detected in the sera of 13, 10, and 10
patients, respectively. Sera from 2, 0, and 5 out of 11 HDs tested
also showed significant levels of IgG reactive to the EGFR479-488,
EGFR729-738, and EGFR1138-1147 peptides, respectively. In addition,
the significant levels of IgG reactive to the EGFR110-118,
EGFR599-607, and EGFR765-776 peptides were detected in sera from
each of four cancer patients as well as a few HDs. The IgG reactive
to the other five peptides was also observed in the sera of several
patients and HDs. These humoral responses to EGFR peptides
were observed in both HLA-A2-positive and -negative subjects,
indicating no apparent HLA-A2 restriction to peptide-reactive IgG
as reported previously (Ohkouchi et al, 2002). In contrast,
significant levels of IgG reactive to the remaining 21 peptides
were not detectable in any of the sera tested (data not shown).
Subsequently, we focused our efforts on the five peptides EGFR110–118,
EGFR479–488, EGFR729–738, EGFR852–861, and EGF-R1138–1147
(490% purity) in the following study.
The peptide specificity of antipeptide IgG to each of the
EGFR110–118, EGFR479–488, EGFR729–738, EGFR852-861, and EGF-
R1138-1147 peptides was confirmed by absorption tests. Representa-
tive results of the peptide specificity for each of the five peptides by
means of the absorption tests are shown in Figure 2 in which the
results on sera from two patients were provided for each peptide.
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was absorbed with a corresponding peptide, but not with an HIV
peptide used as a negative control. We also investigated by an
absorption test whether antipeptide IgG reacts to the whole EGFR
protein. The level of the antipeptide IgG reactive to any of these
peptides, however, was not decreased at all by the absorption test.
Representative results of the two peptides (EGFR479-488 and
EGFR1138-1147) are shown in the lower, right-hand columns of
Figure 2. These results suggest that there was no crossreactivity
between antipeptide IgGs and the whole EGFR protein.
Based on these findings, these EGFR110–118, EGFR479–488,
EGFR599–607, EGFR729–738, EGFR765–776, and EGFR1138–1147 pep-
tides were further tested for their abilities to induce CTL activity in
PBMCs of HLA-A2
þ epithelial cancer patients and HDs (n¼10
and 6). The EGFR813–822 peptide, to which no IgG response was
detectable in sera, was also tested as a control. We judged the
induction to be successful when the supernatant of at least one well
showed more than 100pgml
 1 INF-g production with a statisti-
cally significant difference (P-value of o0.05). The EGFR479–488
and EGF-R1138–1147 peptides induced peptide-specific CTLs in
three and six of 10 cancer patients tested, respectively. Repre-
sentative results (Pts.3, 5, 6, 8, 9, and 10) are shown in Figure 3, in
which the results from each of the four wells are provided.
Background INF-g productions in response to an HIV peptide
(o50pgml
 1) were subtracted. In regard to HLA-A subtypes, two
(Pts.5 and 9), three (Pts.3, 6, and 8), and one (Pt.10) patients were
HLA-A0201, -A0206, and -A0207, respectively (Table 1). The
results indicate that these two peptides had the ability to induce a
peptide-specific cellular response in PBMCs from different HLA-
A2 subtypes. These two peptides, however, were not sufficiently
stimulated to produce significant levels of IFN-g in any of the six
HDs tested. Similarly, each of the other five peptides tested rarely
stimulated PBMCs to produce the significant levels of IFN-g in
either cancer patients or HDs (data not shown).
Sera possessing anti- EGFR479–488 and anti-EGFR1138–1147
peptide activities from the patient 4 and patient 6 were tested for
their capability to directly inhibit growth of 11–18 tumour cells.
As controls, these sera absorbed with a corresponding peptide,
sera without antipeptide activity from the two patients and two
HDs, and FCS were used. However, none of the sera with
antipeptide IgG directly inhibited tumour cell growth in vitro.
Representative results at a serum concentration of 5% are shown in
Figure 4 (left side). We also tested the antibody-dependent cell-
mediated cytotoxicity of antipeptide IgG. Namely, the cytotoxicity
of freshly isolated PBMCs from HLA-A2
þ HDs against T2 cell
pulsed with an EGFR-derived peptide or an HIV peptide as a
negative control was measured in the presence of heat-inactivated
serum possessing antipeptide activity. As controls, these sera
absorbed with a corresponding peptide, sera possessing nonpep-
tide activity, and serum-free RPMI1640 medium were used.
However, the presence of sera possessing anti-EGFR peptide
activity could not increase their cytotoxicity. Representative results
are shown in Figure 4 (right side).
The cytotoxicity of the EGFR479–488 or EGF-R1138–1147 peptide-
stimulated PBMCs was confirmed by a 6-h
51Cr-release assay, and
the representative results of the three patients (Pts.3, 6, and 9) are
shown in Figure 5. These PBMCs showed significant levels of
cytotoxicity against all the 11–18 cells (HLA-A2
þ, EGFR
þ) and
SKOV3-A2 cells (HLA-A2
þ, EGFR
þ), but failed to kill any of the
QG56 cells (HLA-A26, EGFR
þ) or SKOV3 cells (HLA-A3/28,
EGFR
þ) tested. These PBMCs also failed to kill PHA-blastoid T
cells (HLA-A2
þ, EGFR
 ). Peripheral blood mononuclear cells
stimulated with an HIV peptide taken as a negative control did not
show such HLA-A2-restricted cytotoxicity (data not shown). These
results suggest that these PBMCs possess HLA-A2-restricted
cytotoxicity reactive to EGFR
þ tumou cells.
Further, the restriction and peptide-specificity of the cytotoxi-
city were confirmed by inhibition and competition assays,
respectively (Figure 6). Namely, levels of the cytotoxicity mediated
by these peptide-stimulated PBMCs were significantly inhibited by
anti-HLA-class I (W6/32) or anti-CD8mAb, but not by the other
mAbs tested in the assay. The cytotoxicity was also inhibited by the
addition of the corresponding peptide-pulsed T2 cells, but not by
addition of the HIV peptide-pulsed cells. These results suggest that
the CTL activity is largely mediated by the peptide-specific CD8
þ
T cells in an HLA-class I-restricted manner.
DISCUSSION
Among the 29 EGFR-derived peptides tested in this study, two
peptides, one at position 479–488 and the other at position 1138–
1147, were recognised by cellular and humoral immune responses
in at least one-third of PBMCs and half of the sera samples from
HLA-A2
þepithelial cancer patients, respectively. These peptides,
however, rarely induced CTL activity in the PBMCs of HDs,
although IgG reactive to them was detectable in the sera of some
HDs. The reactivity of PBMCs from several of HDs to EGFR
peptides is not particularly surprising, given that EGFR is
expressed not only in epithelial cancer cells but also in certain
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Figure 1 Detection of antipeptide IgG. Optical density values of each
sample were assayed in serially diluted serum samples to estimate peptide-
reactive IgG levels by the ELISA. The OD value against an irrelevant peptide
(HIV) used as a negative control was subtracted from the data.
Representative results of six patients (Pts.3, 4, 5, 6, 8, and 9) are shown.
The cutoff value was set as 0.06 OD value at a serum dilution of 100 times
(the mean (0.02) þ2 s.d. (0.02) of OD value in HDs (n¼11) in response
to an HIV peptide which has an HLA-A2 binding motif taken as a negative
control).
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yTable 1 Humoral responses to the EGFR peptides
Responses to the EGFR peptides (OD values)
a
Subjects HLA Subtype EGFR10–18 EGFR61–70 EGFR110–118 EGFR479–488 EGFR599–607 EGFR653–662 EGFR654–662 EGFR729–738 EGFR765–776 EGFR852–861 EGFR1138–1147
Pt.1 A2/24 A0207 —
b — ———————— —
Pt.2 A2/24 A0206 — — — — — ————— —
Pt.3 A2/24 A0206 — — 0.09 0.15 — — — 0.17 0.08 0.07 0.15
Pt.4 A2/11 A0206 0.26 — 0.08 0.49 — — — 0.10 — — 0.10
Pt.5 A2 A0201 — — 0.09 0.33 — ————— 0.08
Pt.6 A2/24 A0206 — — — 0.22 — — — 0.24 0.10 — 0.14
Pt.7 A2/3 A0201 — — — — — ————— —
Pt.8 A2/24 A0206 — — — 0.07 — — — — 0.16 — 0.07
Pt.9 A2/24 A0201 — — — 0.15 — — — 0.13 — — 0.09
Pt.10 A2 A0207 — 0.07 0.14 0.12 0.13 0.07 — 0.07 — — 0.13
Pt.11 A24/33 — 0.07 — 0.10 0.17 — 0.09 0.17 — — 0.16
Pt.12 A24 — — — 0.21 0.08 ———— — 0.07
Pt.13 A24 — — — — 0.07 ————— —
Pt.14 A24 — — — — — — — — 0.18 — —
Pt.15 A24 — — — 0.55 — — — 0.59 — — —
Pt.16 A24 — — — 0.17 — ————— —
Pt.17 A24/31 — — — 0.24 — — — 0.10 — 0.07 0.10
Pt.18 A24 — — — 0.07 — ————— —
Pt.19 A24/33 — — — — — 1.22 — 0.31 — — —
Pt.20 A24/11 — — — — — — — 0.30 — — —
HD1 A2/24 A0206 — — — — 0.20 — 0.07 — — — 0.13
HD2 A2/24 A0206 — — — — 0.09 ————— —
HD3 A2/11 A0206 — — — 0.26 — ————— —
HD4 A2/26 A0201 — — — 0.13 — ————— 0.08
HD5 A2 A0206 — — — — — ————— —
HD6 A2/24 A0201 — — — — — ————— —
HD7 A24/33 — — — — — ————— —
HD8 A24/26 — — — — — ————— —
HD9 A24/26 0.07 0.07 — — 0.20 — 0.12 — — — 0.26
H D 1 0 A 2 4 — — ———————— 0.17
HD11 A11/33 — 0.09 0.09 — 0.13 — 0.07 — — — 0.15
Antipeptide Abs Pt (n¼20) 1 2 4 13 4 2 1 10 4 2 10
HD(n¼11) 1 2 1 2 4 0 3 0 0 0 5
aAntipeptide IgG was assayed by ELISA as described in Materials and methods. Values represent the OD value at a serum dilution of 100 times.
bThe OD values lower than the cutoff (0.06) are shown as —.
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ynormal epithelial cells (Coussens et al, 1985; Yamamoto et al, 1986;
Salomon et al, 1995). Humoral responses to EGFR in sera of
patients with different malignancies were reported (Bei et al, 1999).
Aberrant expression and activation of EGFR in malignant cells
might lead to breakdown of immunotolerance. Cellular responses
to HER2/neu-derived peptides are also detectable in PBMCs from
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Figure 2 Specificity of antipeptide IgG. Each serum sample was absorbed with either a corresponding peptide or an HIV peptide used as a negative
control three times at 371C followed by testing of peptide-specific IgG activity with ELISA. Results of five peptides in the sera of each two representative
patients from six (Pts. 3, 4, 5, 6, 11, and 17) are shown in the figure. In addition for testing of the peptide-specific IgG activity to whole protein, each serum
sample was absorbed with an EGFR protein (purified from A431 cells), human albumin as a negative control, or a corresponding peptide as a positive
control. The representative results from the sera of Pts.4 and 6 are shown in the lower, right-hand columns of this figure.
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Figure 3 Cellular responses to peptide. Peptide-stimulated PBMCs from HLA-A2
þ cancer patients were cultured in four different wells
(15 10
4well
 1). On day 14 of culture, the peptide-stimulated PBMCs (80 120 10
4well
 1) from each well were independently collected and divided
into four equal portions. Two such portions were separately tested for their ability to produce IFN-g in response to T2 cells pulsed with a corresponding
peptide, while the remaining two portions were tested with a negative control peptide (HIV). Background IFN-g production in response to the HIV peptide
(o50pgml
 1) was subtracted. An asterisk (*) indicates Po0.05 by a two-tailed Student’s t-test. The representative results of six patients (Pts.3, 5, 6, 8, 9,
and 10) are shown.
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HER2/neu peptides were not reported (Fisk et al, 1995; Peoples
et al, 1995; Kawashima et al, 1999; Okugawa et al, 2000). It is of
note, however, that at least one-third of PBMCs and sera samples
from epithelial cancer patients in the present study showed both
cellular and humoral responses to these two peptides, suggesting
that these peptides have higher immunogenecity than any of the
remaining 27 EGFR-derived peptides, which triggered immune
responses only in a few subjects.
In addition to these two peptides, the four peptides, to which
antipeptide IgGs were detectable in the sera of some cancer
patients, were tested for their ability to induce peptide-reactive
IFN-g production in several cancer patients, but none of the four
peptides induced the CTL activity under employed conditions.
Among the four peptides, the EGFR729–738 peptide was recognised
by the majority of patients’ sera, but by none of the sera of the
HDs, suggesting that CD4
þ T cells of cancer patients may be
involved in the antipeptide-specific IgG production. This point
needs to be further studied in order to develop a monoclonal
antibody to this epitope. Cellular responses to the remaining 23
peptides with HLA-A2 binding motifs were not investigated
because of the limited number of PBMCs available for the analysis.
Therefore, further studies will be needed to identify the EGFR-
derived peptides capable of inducing HLA-A2-restricted cellular
response alone.
We previously reported that IgG reactive against CTL epitope
peptides was often detected in the prevaccination sera of cancer
patients and also in the sera of HDs, and there was no obvious
HLA-class I-A restriction involved (Ohkouchi et al, 2002;
Kawamoto et al, 2003; Mine et al, 2003; Noguchi et al, 2003; Sato
et al, 2003). Further, some CTL-directed peptides have shown the
ability to elicit both cellular and humoral immune responses in
vivo in phase I clinical studies, and levels of antipeptide IgG in
postvaccination sera have well correlated with the overall survival
of advanced cancer patients who received peptide vaccination
(Mine et al, 2003; Sato et al, 2003). In contrast, IgG reactive to
these CTL peptides has been reported to be either lacking or
unbalanced in the sera of patients with atopic disease (Kawamoto
et al, 2003). These results suggest that the IgG to these peptides
play a role in host-defence against these diseases, although the
underlying mechanism of the antitumour immune responses in
cancer patients is presently unclear. The underlying mechanisms
of IgG production against CTL epitope peptides in HDs as well as
the disturbance of IgG production in patients with atopic disease
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Figure 4 Direct inhibition and antibody-dependent cell-mediated cytotoxicity of sera possessing antipeptide IgG. (A) To test the direct growth inhibition
activity of antipeptide IgG, 11–18 tumour cells were cultured in the presence of three different concentrations of sera, which had detectable levels of
antipeptide activity. The 11–18 cells at 1 10
3 cellswell
 1 in a 96-well microculture plate (IWAKI, Chiba, Japan) were cultured for 12h in the medium with
10% FCS followed by replacement of the culture medium to serum-free RPMI1640 with 1, 2, or 5% of serum possessing antipeptide activity. As controls, the
same volumes of these sera absorbed with a corresponding peptide as well as sera possessing no antipeptide activity were used for the culture. The 11–18
cells were also cultured in the RPMI with 1, 2, and 5% FCS, respectively. After 24, 48, and 72h incubation, the number of viable cells was determined by Cell
Counting Kit-8 (Dojindo, Kumamoto, Japan). The values are the mean7s.e. of quadruplicate cultures. (B) To test the antibody-dependent cell-mediated
cytotoxicity of antipeptide IgG, the cytotoxicity of freshly isolated PBMCs from HLA-A2
þ HDs against T2 cells pulsed with an EGFR-derived peptide or an
HIV peptide as a negative control was measured in the presence of heat-inactivated serum possessing antipeptide activity by a standard 6-h
51Cr-release
assay. As controls, these sera absorbed with a corresponding peptide, sera possessing nonpeptide activity, and serum-free RPMI1640 medium were used. All
sera used in the cytotoxicity assay were heat-inactivated at 56
1C in 30min. The standard 6-h
51Cr-release assay was performed at three E/T (effector to
target) ratios. The representative results on EGFR479–488 and EGFR1138–1147 peptides are shown in this figure (left side). The results were performed at E/T
ratio 10:1, and the values represent the mean7s.d. of % specific lysis in triplicate assays.
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Figure 5 Cytotoxicity. Peptide-stimulated PBMCs were tested for their cytotoxicity against the following cancer cell lines: 11–18 (HLA-A2
þ, EGFR
þ),
QG56 (HLA-A2
 , EGFR
þ), SKOV3-A2 (HLA-A2
þ, EGFR
þ), and SKOV3 (HLA-A2
 , EGFR
þ). PHA-blastoid T cells (HLA-A2
þ, EGFR
 ) were also used
as a negative control. The standard 6-h
51Cr-release assay was performed at three E/T (effector to target) ratios. The representative results of three cancer
patients (Pts.3, 6, and 9) are shown in the figure. Values represent the mean7s.d. of % specific lysis. An asterisk (*) indicates Po0.05 by a two-tailed
Student’s t-test.
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Figure 6 Inhibition and competition assays. Peptide-stimulated PBMCs were tested for their restriction and peptide-specificity of cytotoxicity against 11–
18 (HLA-A2
þ, EGFR
þ) and QG56 (HLA-A2
 , EGFR
þ) by the standard 6-h
51Cr-release assay. In all, 20mg/ml of anti-HLA-class I (W6/32, IgG2a), anti-
HLA-class II (H-DR-1, IgG2a), anti-CD8 (Nu-Ts/c, IgG2a), and anti-CD4 (Nu-Th/i, IgG1) mAb were used for the inhibition assays. Anti-CD14 (JML-H14,
IgG2a) mAb served as a negative control. For the competition assay, unlabelled T2 cells pulsed with the corresponding peptide or an HIV peptide as a
negative control were added to the
51Cr-release assay at a cold-to-hot target cell ratio of 10:1. The 6-h
51Cr-release assay was performed at an E/T ratio of
10:1. An asterisk (*) indicates Po0.05 by a two-tailed Student’s t-test. Values represent the mean7s.d. of % specific lysis.
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not been found to react to the mother proteins to the degree that
they have been tested, which is in agreement with the present
finding of a lack of anti-EGFR-derived-peptide IgG reactivity in
response to the EGFR protein shown. Sera possessing anti-EGFR-
derived-peptide IgGs also failed to show either direct growth
inhibition of tumour cells in vitro or to elicit antibody-dependent
cell-mediated cytotoxicity to tumour cells to the degree that they
have been tested. Therefore, anti-EGFR-derived-peptide IgGs may
not act directly on tumour cells.
These antipeptide IgGs did not react to the mother protein, and
also failed to show either the direct inhibition of tumour cell
growth in vitro or to elicit antibody-dependent cell-mediated
cytotoxicity to tumour cells as far as tested. It is well known that T
cells in the circulation rarely infiltrate into tumour sites. In
contrast, IgG molecules might easily reach either peritumour sites
or intratumour sites, which in turn facilitate inflammatory
reactions at the tumour cites. This assumption is in part supported
by the recent observation that significant levels of inflammatory
responses were observed around prostate cancers at the time of
surgery in patients who received peptide vaccinations based on
information regarding antibodies reactive to peptides before
radical prostatectomy (Noguchi et al unpublished results). We
also reported that IgG reactive to these CTL-epitope peptides are
either lacking or unbalanced in the sera of patients with atopic
disease (Kawamoto et al, 2003). The results shown in this study
along with those from noncancerous subjects suggests that these
peptide-reactive IgGs play a role in host-defence against various
diseases, although further studies are needed to clarify their
biological role as well as their mechanism of action.
Although further studies are needed to clarify the biological role
as well as the mechanism of action of antipeptide antibodies, the
two peptides recognised by both cellular and humoral immune
responses can be presumed to be more immunogenic than those
recognised by the cellular response alone. The HLA-A2 allele is
found in 40% of Japanese, 50% of Caucasians, and 16% of Africans.
There are several major subtypes of the HLA-A2 allele. The
frequencies of HLA-A0201, -A0206, and -A0207 among HLA-A2-
positive Japanese are about 45, 36, and 17%, respectively, whereas
HLA-A0201 is the predominant subtype among HLA-A2-positive
Western Caucasians (96%), African Blacks (62%), and Sardinian
Caucasians (59%) (Imanishi et al, 1992). These two peptides at
positions 479–488 and 1138–1147 possessed the ability to induce
HLA-A2-restricted and tumour-specific CTLs from PBMCs of
cancer patients with at least the three different HLA-A2 subtypes
shown above.
Epidermal growth factor receptor is highly expressed in a
number of human tumours (Coussens et al, 1985; Yamamoto et al,
1986; Salomon et al, 1995), and many clinical trials of EGFR-
targeted therapies have been going on. In those clinical trials,
various toxicities (mainly, acneiform rash and diarrhoea) were
reported although the frequency and severity of these adverse
events were relatively low (Dittrich et al, 2002; Herbst et al, 2002;
Mendelsohn and Baselga, 2003). We have used self-antigen-derived
peptides, such as SART1, SART3, and lck, in phase I clinical
studies of individualised peptide vaccination for far advanced
cancer patients. In these clinical studies, no severe adverse events,
except for local redness and swelling of injection site, were
observed (Mine et al, 2003; Noguchi et al, 2003; Sato et al, 2003;
Tsuda et al, 2004). Epidermal growth factor receptor-derived
peptides shown in this study are now under clinical trials in our
hospitals as phase I study of individualised peptide vaccination for
far advanced cancer patients, but the vaccination of these EGFR-
peptides was not associated with acneiform rash and diarrhoea.
However, careful observation throughout the phase I study is
needed to obtain the safety of these peptides. The phase II study
with these peptides is planned to see whether EGFR is one of
attractive targets for immunotherapy for far advanced epithelial
cancer patients or not.
In conclusion, these findings may provide new insight for the
development of an EGFR-based immunotherapy beneficial for
substantial numbers of epithelial cancer patients throughout the
world.
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